• Latest Posts

Sanofi drug reduces disease activity in relapsing MS

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

ADVERTISEMENT

First-ever Marketing Authorization Application for biosimilar targeting MS filed

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls

Phase III Fail for MedDay’s Multiple Sclerosis Treatment

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

ADVERTISEMENT